NEWS CENTER
Check category
-
News
Big News! SyncoZymes (Shanghai) Co., Ltd , The world's first NMN raw material passed FDA NDI certification.

Big News! SyncoZymes (Shanghai) Co., Ltd , The world's first NMN raw material passed FDA NDI certification.

After strict review by the professional committee of the US FDA (US Food and Drug Administration) authoritative organization, on May 17, 2022, SyncoZymes (Shanghai) Co., Ltd. officially received the FDA's confirmation letter (AKL): NMN raw material successfully passed NDI (New Dietary Ingredient) approval.

MORE
03

2022-08

Big news: Syncozymes has an annual output of 100 tons of coenzyme NMN/NADH/NAD series. These ingredients will be put into production

Syncozymes's annual production of 100 tons of coenzyme NMN/NADH/NAD series products will be officially put into production in October this year!

15

2021-01

Good news: Shangke Bio has been recognized as a high-tech achievement transformation project

On January 5, 2021, Shangke Biopharmaceutical (Shanghai) Co., Ltd. was awarded the "(S)-1-tert-butoxycarbonyl-3-hydroxypiperidine" Shanghai High-tech Achievement Transformation Project.

13

2020-11

[During the Expo]: Shangke Bio won the title of the first batch of enterprises to settle in the "Global Matchmaking Club"

The "Global Matchmaking Club" cross-border matchmaking platform is independently developed by ICBC and is open to global enterprises free of charge. Matching activities” and other core functions. Since the platform was launched for more than two months, it has attracted nearly 20,000 enterprises to settle in, covering more than 40 countries and regions, covering more than 30 industries such as food and medicine, energy and chemical industry, and technical equipment. The platform is committed to conforming to the general trend of open and cooperative world economic development, serving the new development pattern with the concept of inclusive finance, and continuously contributing financial positive energy to the building of an open world economy.

28

2020-10

Shangke Bio and Zhejiang Supor Pharmaceutical Co., Ltd. participated in the 2020 Nanjing API CHINA API Exhibition and made a special academic report on NMN

On October 14, 2020, the 85th China International Pharmaceutical API/Intermediate/Packaging/Equipment Fair (referred to as API China API) opened at the Nanjing International Expo Center. Shangke Bio and Zhejiang Supor Pharmaceutical Co., Ltd. participated in the 2020 Nanjing API CHINA API Exhibition. Dr. Zhu, General Manager of Shangke Biology, made a special academic report on "NMN's Past, Present and Future" at the exhibition.

20

2020-10

[Good news] Shangke Bio's NMN products have passed the safety certification of SELF GRAS in the United States

In September 2020, Shangke Bio's NMN products passed the SELF GRAS (US Safety Index for Evaluation of Food Additives) safety certification. NMN has been dubbed the "elixir" by the public, and its main function is to repair DNA, healthy cells, and relieve various diseases caused by aging.

Pre
1
2
Big News! SyncoZymes (Shanghai) Co., Ltd , The world
Big News! SyncoZymes (Shanghai) Co., Ltd , The world's first NMN raw material passed FDA NDI certification.
After strict review by the professional committee of the US FDA (US Food and Drug Administration) authoritative organization, on May 17, 2022, SyncoZymes (Shanghai) Co., Ltd. officially received the FDA's confirmation letter (AKL): NMN raw material successfully passed NDI (New Dietary Ingredient) approval.
Read more >>
Big news: Syncozymes has an annual output of 100 tons of coenzyme NMN/NADH/NAD series. These ingredients  will be put into production
Big news: Syncozymes has an annual output of 100 tons of coenzyme NMN/NADH/NAD series. These ingredients will be put into production
Syncozymes's annual production of 100 tons of coenzyme NMN/NADH/NAD series products will be officially put into production in October this year!
Read more >>
Good news: Shangke Bio has been recognized as a high-tech achievement transformation project
Good news: Shangke Bio has been recognized as a high-tech achievement transformation project
On January 5, 2021, Shangke Biopharmaceutical (Shanghai) Co., Ltd. was awarded the "(S)-1-tert-butoxycarbonyl-3-hydroxypiperidine" Shanghai High-tech Achievement Transformation Project.
Read more >>
[During the Expo]: Shangke Bio won the title of the first batch of enterprises to settle in the "Global Matchmaking Club"
[During the Expo]: Shangke Bio won the title of the first batch of enterprises to settle in the "Global Matchmaking Club"
The "Global Matchmaking Club" cross-border matchmaking platform is independently developed by ICBC and is open to global enterprises free of charge. Matching activities” and other core functions. Since the platform was launched for more than two months, it has attracted nearly 20,000 enterprises to settle in, covering more than 40 countries and regions, covering more than 30 industries such as food and medicine, energy and chemical industry, and technical equipment. The platform is committed to conforming to the general trend of open and cooperative world economic development, serving the new development pattern with the concept of inclusive finance, and continuously contributing financial positive energy to the building of an open world economy.
Read more >>
Shangke Bio and Zhejiang Supor Pharmaceutical Co., Ltd. participated in the 2020 Nanjing API CHINA API Exhibition and made a special academic report on NMN
Shangke Bio and Zhejiang Supor Pharmaceutical Co., Ltd. participated in the 2020 Nanjing API CHINA API Exhibition and made a special academic report on NMN
On October 14, 2020, the 85th China International Pharmaceutical API/Intermediate/Packaging/Equipment Fair (referred to as API China API) opened at the Nanjing International Expo Center. Shangke Bio and Zhejiang Supor Pharmaceutical Co., Ltd. participated in the 2020 Nanjing API CHINA API Exhibition. Dr. Zhu, General Manager of Shangke Biology, made a special academic report on "NMN's Past, Present and Future" at the exhibition.
Read more >>
[Good news] Shangke Bio
[Good news] Shangke Bio's NMN products have passed the safety certification of SELF GRAS in the United States
In September 2020, Shangke Bio's NMN products passed the SELF GRAS (US Safety Index for Evaluation of Food Additives) safety certification. NMN has been dubbed the "elixir" by the public, and its main function is to repair DNA, healthy cells, and relieve various diseases caused by aging.
Read more >>
Zhejiang Shangke Biopharmaceutical Co., Ltd. The enzyme catalysis project passed the preliminary review of the key research and development plan of Zhejiang Province
Zhejiang Shangke Biopharmaceutical Co., Ltd. The enzyme catalysis project passed the preliminary review of the key research and development plan of Zhejiang Province
In August 2020, the "Bio-enzyme Library Development and Green Catalytic Synthesis Application" project of Zhejiang Shangke Biopharmaceutical Co., Ltd. passed the preliminary review of the Zhejiang Provincial Key R&D Program of the Zhejiang Provincial Department of Science and Technology.
Read more >>
Shangke Bio
Shangke Bio's NMN raw material passed the "Acute Oral Toxicity Test"
The recent outbreak of the concept of "longevity medicine" NMN has caused shocks in the capital market. In mid-July, the "Internet celebrity longevity medicine" NMN concept stock became a dark horse in the market. The stocks of related companies have been closed one after another, and a listed company has gained 8 daily limits in 11 days.
Read more >>
Research progress on enzymatic synthesis of potential precursors of Clenbuterol in cooperation between Norwegian University of Science and Technology and Shangke Biomedical
Research progress on enzymatic synthesis of potential precursors of Clenbuterol in cooperation between Norwegian University of Science and Technology and Shangke Biomedical
Clenbuterol, is a β2-adrenergic agonist (β2-adrenergic agonist), similar to ephedrine (Ephedrine), is often used clinically to treat chronic obstructive pulmonary disease (COPD), It is also used as a bronchodilator to relieve acute exacerbations of asthma.
Read more >>
Previous page
1
×

Search

Search
×